Ankylosing spondylitis

Ankylosing spondylitis

BioCertica Content Team

Ankylosing spondylitis is a chronic autoimmune disorder that primarily affects the spine. The condition is characterized by pain, stiffness, and inflammation in the back, sacroiliac joints, and neck, which can lead to restricted mobility and impaired quality of life. In addition to these symptoms, individuals with ankylosing spondylitis may also experience fatigue, fever, and weight loss.

The onset of ankylosing spondylitis typically occurs in young adulthood, with symptoms starting between the ages of 17 and 35 years. Initially, individuals may experience intermittent episodes of back pain and stiffness that improve with exercise or activity. However, as the condition progresses, the pain and stiffness may become more persistent and severe, leading to a reduced range of motion and difficulty with daily activities.

As ankylosing spondylitis progresses, the inflammation can also affect other joints in the body, such as the hips, knees, and shoulders. In some cases, the condition may also affect organs such as the eyes, heart, and lungs.

If you are experiencing symptoms of ankylosing spondylitis, it's important to consult with your healthcare provider for proper diagnosis and treatment. Treatment for ankylosing spondylitis typically involves a combination of medication, physical therapy, and exercise to reduce pain, improve mobility, and prevent further damage to the spine and other joints.

While the exact cause of ankylosing spondylitis is not fully understood, research has shown that genetic factors play a significant role in its development. In fact, individuals with a family history of this condition are at a higher risk of developing it themselves.

Several genes have been identified as potential contributors to the development of ankylosing spondylitis. The most significant of these genes is the HLA-B27 gene, which is found in up to 95% of people with the condition. However, having the HLA-B27 gene does not necessarily mean that an individual will develop ankylosing spondylitis. Other genetic and environmental factors may also be involved.

The HLA-B27 gene is responsible for producing a protein that helps the immune system recognize foreign substances in the body. In individuals with ankylosing spondylitis, the HLA-B27 protein may trigger an autoimmune response that attacks healthy tissues in the spine and other joints, leading to inflammation and pain.

While genetic factors are important in the development of ankylosing spondylitis, environmental factors may also play a role. For example, smoking has been shown to increase the risk of developing the condition in individuals with the HLA-B27 gene.

AS is diagnosed through a combination of physical examination, laboratory tests, and imaging tests, such as X-rays, CT scans, and MRIs. The condition usually starts in the late teens or early 20s. 

Treatment for AS focuses on reducing inflammation and managing symptoms. This can include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and biological drugs. Physical therapy can also help to increase mobility, decrease pain, and improve overall function.

In conclusion, ankylosing spondylitis is a chronic autoimmune disorder that primarily affects the spine. Genetic factors play a significant role in its development. By having your genetic predisposition tested, you may be enabled to detect the condition earlier if it does develop. This way, you can get treatment earlier for a better prognosis.



Interested in trying the BioCertica DNA Autoimmune kit? Click here and add Autoimmune Diseases to your cart for only R1699. 

If you own any other BioCertica DNA kit, you can instantly unlock your Autoimmune Disease results for only R659* in-app.

*Terms and conditions apply: Pharmacogenetics results are R1999 in-app.

Back to blog

Check out some of our DNA kits below.

1 of 3